When will the FDA approve Intellia Therapeutics' lonvo-z?

Kalshi Health › FDA & drugs Closes Dec 31, 2027 · $5.9K traded · $3K at stake · prices read 3 h ago

The odds

91%Before October 2027

Before October 202791%
Before 202891%
Before July 202789%▲ 1

How the odds have moved

Before October 2027: 90% on Oct 20, 91% now.

Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.

Every outcome

Outcome	Chance	Day	Bid	Ask	Pays	Contracts
Before October 2027	91%		89¢	93¢	$1.08	1.1K
Before 2028	91%		89¢	92¢	$1.09	707
Before July 2027	89%	▲ 1	87¢	91¢	$1.10	4.7K

"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".

The news: FDA, Intellia Therapeutics, Lonvoguran Ziclumeran

Search ›

Intellia Therapeutics Receives FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran For Hereditary AngioedemaMarketScreener · 3 days agoIntellia Therapeutics, Inc. announced the U.S. Food and Drug Administration has accepted the Biologics License Application for lonvo-z and granted the BLA Priority Review with a Prescription Drug... Food and Drug Administration (FDA) has…
Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary AngioedemaMarketScreener · 3 days agoIntellia Therapeutics said Tuesday that the US Food and Drug Administration has accepted the biologics license application for lonvo-z for the treatment of hereditary angioedema. The FDA has also... Biotechnology & Medical Research…
Intellia Therapeutics, Inc. announced that it expects to receive $400 million in fundingMarketScreener · 3 days agoIntellia Therapeutics, Inc. announced that it has has entered into a $400 million credit agreement with new lenders, OrbiMed Royalty & Credit Opportunities V, LP, fund managed by OrbiMed Advisors LLC... announced that it has has entered…
FDA approves Orladeyo berotralstat pellets for hereditary angioedema in older age groupshealiotwo · 3 days agoThe FDA approved berotralstat oral pellets for prophylactic use in patients aged 12 years and older with hereditary angioedema, according to a press release from BioCryst Pharmaceuticals. As Healio previously reported, the once-daily 150…
Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)Markets Daily · 2 days agoPosted by Tristan Rich on Oct 24th, 2026 Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) and Neurogene (NASDAQ:NGNE – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
Intellia Therapeutics, Inc.: Relative Strength Chart - Stock NasdaqMarketScreener · 3 days agoCompare Intellia Therapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time NTLA price, Nasdaq stock exchange Relative Strength Chart Intellia Therapeutics, Inc. Biotechnology & Medical Research All…
Barclays Initiates Intellia Therapeutics at Underweight With $8 Price TargetMarketScreener · 3 days agoIntellia Therapeutics has an average rating of overweight and mean price target of $22.88, according to analysts polled by FactSet. ... Biotechnology & Medical Research Barclays Initiates Intellia Therapeutics at Underweight With $8 Price…
Transcript : Intellia Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026MarketScreener · 3 days agoPresentation Operator MessageOperator Hello, and welcome to Intellia Therapeutics Second Quarter Conference Call. My name is Chloe, and I will be your conference operator today. Please be advised Transcript : Intellia Therapeutics, Inc…
Intellia Therapeutics Enters $400 Million OrbiMed Term Loan FacilityMarketScreener · 3 days agoIntellia Therapeutics entered a $400 million non-dilutive senior secured term loan facility with OrbiMed to support key clinical and commercial milestones, the company said Friday. The facility... Biotechnology & Medical Research Intellia…
Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral RatingMarketScreener · 3 days agoPrice: 10.97, Change: -0.35, Percent Change: -3.09 ... Biotechnology & Medical Research Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating Published on 08/06/2026 at 11:09 am EDT
Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral RatingMarketScreener · 3 days agoIntellia Therapeutics has an average rating of overweight and mean price target of $26.85, according to analysts polled by FactSet. Price: 12.82, Change: +0.08, Percent Change: +0.63 ... Biotechnology & Medical Research Wedbush Adjusts…
Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral RatingMarketScreener · 3 days agoPrice: 15.51, Change: -1.33, Percent Change: -7.90 ... Biotechnology & Medical Research Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating Published on 07/09/2026 at 12:12 pm EDT

Related markets

All fda & drugs ›

Health › FDA & drugs

Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)

14%chance▼ 2

Health › FDA & drugs

Will the FDA approve retatrutide? (retatrutide (LY3437943))

Oct 22, 2027even chance by

Before Jan 1, 20274%
Before Jul 1, 202718%
Before Jan 1, 202871%

2 more

Before Jul 1, 202885%
Before Jan 1, 202990%

Health › FDA & drugs

When will the FDA reclassify BPC-157 to Category 1?

21%Before 2027

Before 202721%▼ 1
Before November7%▼ 1

Health › FDA & drugs

FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)

92%chance▲ 1

Health › FDA & drugs

When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)

89%Before 2028

Before 202889%▲ 1
Before October 202786%▲ 1
Before July 202785%

2 more

Before Mar 1, 202762%▲ 1
Before Jan 1, 202724%

Health › FDA & drugs

Will the FDA approve MDMA for PTSD?

Oct 24, 2028even chance by

Before Jan 1, 202710%
Before Jan 1, 202842%
Before Jan 1, 202952%▲ 1

3 more

Before Jan 1, 203053%▲ 1
Before Jan 1, 203153%▲ 1
Before Jan 1, 203253%

Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Search. Prices read from the venues 4 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.

About this market

VenueKalshi

Settles onU.S. Food and Drug Administration., FDA, Intellia Therapeutics

Trading closesDec 31, 2027 11:59 PM ET

Traded$5.9K (6,562 contracts)

This week$23

At stake$3K

In the news52 headlines today, 842 this week

Followed here sinceOct 19, 2026

The rules

If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.

The full rules are on the market's page at Kalshi.

Reading the odds

A prediction market trades contracts that pay $1 if something happens. Its price is the market's chance: a contract at 62¢ means traders give it 62%. Each number here is the midpoint between the best bid and offer, or the last trade when they are more than ten cents apart.

For a question with many answers (who wins, which range a number lands in), the chances are scaled to add up to 100%. A price ladder ("above 4.25%, above 4.50% ...") gives a whole distribution: its median is where traders see an even chance either way.

Kalshi is a U.S. exchange regulated by the CFTC; its money is counted in contracts, shown here as dollars at their price. Polymarket counts dollars. ForecastEx is Interactive Brokers' exchange, regulated by the CFTC; its contracts too are shown as dollars at their price. Crypto.com lists its markets on Crypto.com | Derivatives North America, a U.S. exchange regulated by the CFTC; it reports the dollars traded. Where more than one asks the same question, each is shown, never averaged.

Prefer betting odds? Switch to American (+150) or decimal (2.50) odds at the top of the page.

Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Search, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Search index; prices of stocks, rates and coins from 4Search Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions